| Industry | Specialty Chemicals |
| Sector | Materials |
| Main Index | AEX25 |
| Company's (investor relations) website | Company Website |
| Next earnings report | NaT |
| Reporting currency | EUR |
| Fiscal year period | 01/01-31/12 |
| Reporting cycle | Quarter |
| Last processed report | Q1-2022 |
| Market Capitalization (in million) | € 13,056 |
| Enterprise value | € 14,246 |
| Shares outstanding (in million) | 181.6 |
| ROE (Return on Equity) | 14.7% |
| ROA (Return on Assets) | 4.9% |
| EPS (Earnings Per Share) | € 4.48 |
| PE (Price/Earnings) | 19.2 |
| Beta | 1.16 |
| Implicit value range | 0.388079661949007|
| Investment advice | Sell |
| Trading advice (based on moving averages) | Hold |
| Latest StockAdvisor Algorithmic advice see Return on Advice Graph | Buy |
| Fundamental Strength (scale 0 - 100) | 69 |
| Trading Strength (scale 0 - 100) | 59 |
| 1 year performance | 1.31% |
| 52 Weeks range | € 61.42 - 78.82 |
| 10 Day's Moving Average | Uptrend |
| 50 Day's Moving Average | Uptrend |
| 200 Day's Moving Average | Downtrend |
| Revenue (last year in million) | € 9,587 |
| 5 year Revenue growth (5 year CAGR) | -10.51% |
| Net income (last year in million) | € 829 |
| 5 year Net income growth (5 year CAGR) | -9.4% |
| 1 year target | € 50.74 |
| 3 year target | € 39.21 |
| Akzo Nobel N.V. based in the Netherlands, operates as a paints and coatings company in the Netherlands and internationally. The company is one of the world's largest producers in and coating. Around 35% of sales are generated in mature Europe, while its Asia-Pacific division has grown quickly to more than 30% of sales. Construction-related end markets are the most important, but meaningful revenue is also generated from the industrial, consumer goods, and transportation markets. |
| Akzo Nobel N.V. |
| Arkema S.A. |
| Corbion N.V. |
| Covestro AG |
| CropEnergies AG |
| Encres Dubuit |
| Evonik Industries AG |
| Fuchs Petrolub SE |
| Description | 2020 | 2021 | 2022 | 2023 * | 2024 * | 2025 * |
| Revenue | € 8,530 | € 9,587 | € 10,345 | € 10,873 | € 11,319 | € 11,682 |
| Net income | € 647 | € 829 | € 679 | € 580 | € 507 | € 445 |
| EPS | € 3.38 | € 4.48 | € 3.62 | € 3.10 | € 2.70 | € 2.37 |
| PE | 25.99 | 21.54 | 19.18 | 18.82 | 18.78 | 18.78 |
| Prices eoy | € 87.86 | € 96.50 | € 69.44 | € 58.26 | € 50.74 | € 44.55 |
| Dividend | € 1.92 | € 6.75 | € 6.40 | € 1.67 | € 3.91 | € 1.37 |
| Div-% | 2.2% | 7.0% | 9.2% | 2.9% | 7.7% | 3.1% |
| Description | Q1-22 | Q2-22 * | Q3-22 * | Q4-22 * | Q1-23 * | Q2-23 * | Q3-23 * | Q4-23 * |
| Revenue | € 2,525 | € 2,583 | € 2,600 | € 2,637 | € 2,663 | € 2,695 | € 2,744 | € 2,772 |
| Net income | € 154 | € 191 | € 170 | € 164 | € 146 | € 145 | € 148 | € 141 |
| EPS | € 0.82 | € 1.02 | € 0.91 | € 0.88 | € 0.78 | € 0.77 | € 0.79 | € 0.75 |
| PE | 18.87 | 16.60 | 19.69 | 19.18 | 18.59 | 18.51 | 18.99 | 18.82 |
| Prices eoq | € 78.22 | € 62.62 | € 58.32 | € 69.44 | € 66.55 | € 61.75 | € 61.12 | € 58.26 |
| NORM | ||||
| Description | Actuals | Progressive | Neutral | Conservative |
| Solvency | 45.1% | < 25% | 25-35% | > 35% |
| ROE (return on equity) | 10.9% | > 12% | 10-12% | < 10% |
| ROA (return on assets) | 4.9% | > 5% | 5% | < 5% |
| Current ratio | 1.6 | < 1 | 1-1.5 | > 1.5 |
| Turnover rate | 1.5 | < 1 | 1-1.5 | > 1.5 |
| WACC | 19.75% | > 10% | 10% | < 10% |
| Beta | 1.16 | > 1 | 1 | < 1 |